Fact-checked by Grok 2 weeks ago

Amniotic fluid

Amniotic fluid is a clear, slightly yellowish contained within the that surrounds and cushions the developing during , providing essential protection and support for fetal growth. It forms early in and evolves in composition and volume to meet the changing needs of the and . The primary functions of amniotic fluid include safeguarding the fetus from mechanical trauma and compression, maintaining a stable to prevent loss, and enabling free movement that promotes proper musculoskeletal development. Additionally, it supports the maturation of vital organs such as the lungs, kidneys, and by supplying nutrients, electrolytes, and growth factors while offering antibacterial properties to reduce infection risk. In terms of composition, amniotic fluid is approximately 98% and electrolytes, with the remaining 2% consisting of organic compounds like proteins, peptides, carbohydrates, , hormones, and signaling molecules that facilitate fetal . Its sources shift during : initially derived from maternal and coelomic , it later becomes predominantly fetal (after about 16 weeks) supplemented by lung and oral-nasal secretions, with the fetus recycling it through and intramembranous absorption. Volume typically peaks at around 800 mL near 34 weeks of before declining slightly to an average of 600 mL at full term, reflecting a dynamic balance essential for fetal well-being. Deviations in amniotic fluid volume, such as (excess fluid, often exceeding 24 cm via ) or oligohydramnios (insufficient fluid, below 5 cm), occur in approximately 5-10% of pregnancies and can signal underlying issues like fetal anomalies, placental dysfunction, or maternal conditions, necessitating ultrasound monitoring and potential interventions.

Formation and Composition

Origin and Production

Amniotic fluid initially forms during the first through transudation of maternal across the fetal and amniotic membranes, driven by osmotic and hydrostatic pressure gradients. This process begins shortly after implantation, with fluid derived primarily from maternal serum and coelomic cavity contributions, providing an early nutrient reservoir that diminishes by around 12 weeks of . A significant shift in production sources occurs between 12 and 16 weeks of , as the fetal skin begins to keratinize, reducing transudation, and fetal-derived fluids become predominant. By the third , fetal accounts for approximately 80% of amniotic fluid volume, with production rates increasing from about 5 mL per hour at 20 weeks to approximately 28 mL per hour (400–800 mL per day) at , reflecting renal maturation. Additional fetal contributions include secretions (up to one-third of volume near , at 300–400 mL per day) and oral-nasal secretions, while residual skin transudation plays a minor role post-keratinization. Fetal , which commences around 11–16 weeks, plays a crucial role in maintaining by removing 200–500 mL per day near , with the fluid recycled through the and reabsorbed via the or intramembranous pathways. Maternal contributions persist throughout via limited across the and bidirectional water exchange (up to 400–500 mL per hour at ), supporting overall . The production timeline thus progresses from maternal-dominated in early , to a balanced mid- phase, and fetal-dominated in late . Key transport mechanisms involve aquaporins (AQPs), water channel proteins such as AQP1, AQP3, AQP8, and AQP9, expressed in , , and vascular endothelium, facilitating rapid transcellular water movement in response to osmotic gradients. These channels enable intramembranous and placental , with expression patterns varying across —AQP1 peaking mid-gestation in ovine models and AQP3 increasing toward term—helping regulate without directly producing the fluid itself.

Chemical and Cellular Components

Amniotic fluid consists predominantly of (approximately 98-99%), along with , solutes, proteins, and cellular components, creating a dynamic milieu that evolves across . Early in , its composition closely mirrors maternal , but by the second , contributions from fetal sources lead to distinct characteristics, such as reduced and protein content compared to . The fluid's and makeup supports , while its cellular elements reflect fetal development. The electrolyte composition features sodium at around 135 mEq/L, at 4.6 mEq/L, and at approximately 106-110 mEq/L, levels that are broadly similar to those in maternal but occur in a protein-poor (total protein ~0.5 g/dL). This low protein concentration, primarily including and (produced by the fetal liver and ), contrasts with the higher protein levels in (~6-8 g/dL) and contributes to the fluid's clarity and low . , such as those from fetal gastrointestinal and pulmonary secretions, are also present in trace amounts, aiding in the breakdown of within the fluid. Unlike maternal , amniotic fluid exhibits lower overall protein and immunoglobulin concentrations, though it contains select maternal-derived immunoglobulins for immune support. Organic components encompass glucose (typically 20-30 mg/dL lower than maternal levels), , , , and phospholipids like and , with concentrations of and rising progressively due to increasing fetal renal output. These solutes maintain metabolic balance, with levels reflecting fetal energy status. The ranges from 7.0 to 7.5, slightly alkaline, and osmolarity is about 280 mOsm/L in mid-gestation, becoming hypo-osmolar (250-270 mOsm/L) in late compared to the stable 285-295 mOsm/L of maternal ; this shift differs from fetal , which is even more hypo-osmotic with lower densities. Cellular elements include desquamated fetal epithelial cells from the skin and , particles of (a lipid-rich from fetal sebaceous glands), and occasional squamous cells, with rare presence of meconium-stained particles or blood cells in uncomplicated pregnancies. These components are sparse, with cell counts typically under 100 per , distinguishing amniotic fluid from more cellular-rich fluids like fetal , which lacks vernix but contains urinary .

Physiological Functions

Protective Mechanisms

Amniotic fluid serves as a critical barrier, shielding the developing from various environmental threats within the . Its primary protective functions include mechanical cushioning, antimicrobial defense, thermal regulation, and facilitation of unrestricted , all of which contribute to and organ protection throughout . One key mechanism is mechanical cushioning, where the fluid acts as a against and external trauma, thereby reducing compression on fetal organs and the . This buoyancy provided by the fluid equalizes pressure around the , minimizing the risk of cord compression that could impair blood flow and oxygenation. Amniotic fluid also exhibits robust antimicrobial properties, containing innate immune components such as beta-defensins, , and immunoglobulins transferred from the maternal circulation. Human beta-defensin-2, in particular, participates in the host response to microbial invasion by inhibiting in the amniotic cavity. Thermal stabilization is another vital function, with the fluid's high water content and helping to buffer temperature fluctuations and maintain the fetal core approximately 0.5°C higher than the maternal . This stable thermal environment supports consistent metabolic processes and prevents heat stress during . Furthermore, the fluid promotes free by providing a lubricated , preventing adhesions between the fetal , organs, and amniotic membranes that could otherwise lead to developmental restrictions. Its , derived from glycoproteins and other components, aids in this anti-adhesive role without causing excessive friction. From an evolutionary perspective, amniotic fluid represents a vestigial aquatic milieu, echoing the marine origins of life and enabling mammalian embryos to develop in a protected, fluid-filled akin to an internal . This adaptation, unique to amniotes, allows terrestrial while recapitulating an aqueous developmental niche.

Developmental and Nutritional Roles

Amniotic fluid plays a critical role in promoting fetal development by providing a medium that facilitates fetal breathing movements, which begin around 10-12 weeks of and help expand the alveoli while stimulating production essential for postnatal . These movements generate pressure changes within the s, maintaining their distension and supporting epithelial and vascularization. Fetal , contributing up to one-third of amniotic fluid volume in late , further aids this process by distending the airways and promoting . The fluid environment of the enables free , which is vital for musculoskeletal by preventing adhesions and contractures in joints and limbs. This allows for symmetric of muscles and bones, as restricted movement in low-fluid conditions can lead to deformities such as . By providing space for spontaneous activity from the second onward, amniotic fluid supports the maturation of the skeletal system and . Fetal swallowing of amniotic fluid, initiating as early as 11 weeks and increasing to approximately 500 mL per day by , is essential for gastrointestinal maturation by stimulating , , and epithelial renewal in the gut. This process introduces trophic factors, peptides, and nutrients that promote villus growth and mucosal development, contributing to the functional readiness of the digestive tract for postnatal feeding. Swallowed fluid also aids in regulating amniotic volume while fostering inoculation in the intestine. Amniotic fluid serves as a medium for to the through across and , delivering glucose, , and fatty acids derived from maternal circulation via the . These solutes, present in concentrations reflecting maternal levels, support fetal energy needs and biosynthetic processes, with swallowed fluid providing up to 10-14% of daily nutritional requirements in late . Electrolytes, carbohydrates, and in the fluid further facilitate metabolic . The acoustic properties of amniotic fluid transmit low-frequency maternal sounds, such as speech and , to the starting from around 23 weeks, aiding development and language exposure. This fluid-mediated conduction filters higher frequencies while amplifying relevant maternal voices, promoting neural maturation in the and through bone and tissue pathways. Amniotic fluid facilitates the exchange of hormones, including and hormones, influencing fetal and organ maturation. diffuse into the fluid from maternal and fetal sources, supporting and skeletal by regulating cellular and . hormones, such as and progesterone derivatives, modulate , maturation, and stress responses, with fluid levels reflecting placental transfer and fetal production to maintain endocrine balance.

Dynamics During Pregnancy

Volume Changes and Measurement

Amniotic fluid volume undergoes dynamic changes throughout , starting low in the first trimester and increasing progressively before peaking and then declining toward . At approximately 10 weeks of , the volume is typically 10-20 mL, rising to around 60 mL by 12 weeks and 175-250 mL by 16 weeks as fetal urine production begins to contribute significantly. By the mid-second trimester, around 24 weeks, the average volume reaches about 500 mL, and it peaks at 800-1000 mL between 34 and 36 weeks. In the third trimester, volume stabilizes or slightly increases until about 35 weeks before declining to 500-600 mL at (40 weeks), reflecting reduced fetal and increased . Several physiological factors influence normal variations in amniotic fluid volume. is the primary determinant, with volume correlating closely with fetal size and renal maturation in early . Fetal may subtly affect volume, with some evidence indicating slightly higher levels in male fetuses due to differences in patterns or hormonal influences. Maternal status impacts volume through transplacental exchange, where even mild can reduce levels, while oral can transiently increase them. Placental function plays a key role by regulating transfer from maternal circulation to the fetal compartment, maintaining osmotic balance essential for volume . The standard clinical method for assessing amniotic fluid is , which provides a non-invasive estimate without direct sampling. The (AFI), introduced by Phelan et al. in 1987, involves dividing the into four s using the and a transverse line through the umbilicus, then measuring the deepest vertical pocket of fluid free of fetal parts or cord in each quadrant; the sum of these measurements yields the AFI in centimeters. Normal AFI ranges vary by : 8-18 cm in the second (peaking around 14 cm from 20-35 weeks), and 5-25 cm overall in the third , with values below 5 cm indicating and above 25 cm suggesting excess fluid. An alternative technique, the single deepest pocket (SDP) measurement, evaluates the largest vertical pocket in any quadrant, with normal values exceeding 2 cm (typically 2-8 cm); this method is simpler and less affected by but correlates less strongly with total than AFI. The four-quadrant assessment inherent to AFI remains the most widely adopted due to its reproducibility and correlation with perinatal outcomes. As adjuncts to ultrasound, non-invasive clinical measures like symphysis-fundal height (SFH) and maternal weight gain can provide indirect clues to volume status, particularly in resource-limited settings. SFH, measured from the to the uterine fundus, correlates with both fetal growth and amniotic fluid volume, with discrepancies (e.g., ≥3 cm below expected for ) prompting further evaluation. Maternal weight trends, when tracked serially, may reflect and , though they lack the precision of sonographic methods.

Circulation, Renewal, and Rupture

Amniotic fluid undergoes continuous circulation and renewal throughout , maintaining a dynamic balance between and to support fetal . In the third , the turnover rate is approximately 700-1200 mL per day, achieved through fetal (primarily contributing 500-700 mL/day at term) and secretions (adding 250-300 mL/day), balanced by mechanisms. This renewal prevents stagnation and ensures the fluid remains to fetal , with occurring at rates of 400-500 mL per hour via and across membranes. Key reabsorption pathways include fetal swallowing via the , which accounts for 200-450 mL/day at term and begins as early as 11-16 weeks of , allowing the to ingest and process for and gut maturation. Intramembranous absorption, where moves directly from the amniotic cavity into the across the chorionic plate and umbilical vessels, contributes significantly, estimated at 400-600 mL/day, and becomes the dominant route after keratinization around 25 weeks. Additionally, fetal movements cycle amniotic at approximately 200-400 mL/kg/day, aiding pulmonary development through inhalation and exhalation into the , with minimal net . Transmembranous pathways, involving across the and , provide minor but continuous exchange with maternal circulation. Rupture of membranes (ROM) marks the terminal phase of amniotic fluid dynamics, typically occurring spontaneously at term as a physiological prelude to labor. This event is triggered by a combination of hormonal changes, including increased prostaglandin synthesis in the decidua and chorioamniotic membranes, which promotes cervical ripening and membrane weakening, and elevated oxytocin levels that enhance uterine contractility and further stimulate prostaglandin release. Mechanical stress from fetal head descent and uterine expansion also contributes, leading to membrane thinning and eventual tearing. ROM can be complete, resulting in a sudden gush of fluid, or partial, with slower leakage; preterm premature ROM (PPROM) complicates about 8-10% of preterm births and 2-3% of all pregnancies overall. Following rupture, amniotic fluid leaks from the vaginal canal due to loss of the containing barrier, with most cases at term progressing to labor onset within 24 hours through coordinated . Diagnostic confirmation relies on bedside tests: the test detects the pH shift to greater than 6.0 (turning the indicator blue) due to amniotic fluid's alkaline nature compared to vaginal secretions, with accuracies of 87-97%. The identifies characteristic arborized patterns under when dried amniotic fluid is examined, offering sensitivities of 74-100% and specificities of 77-100%. These tests enable rapid verification without invasive procedures.

Clinical Evaluation

Collection Techniques

Amniocentesis, the primary method for collecting amniotic fluid, was first performed in 1956 by Fritz Fuchs and Povl Riis to determine fetal in cases of incompatibility, marking the beginning of its use in prenatal . The involves transabdominal insertion of a needle into the under continuous guidance to visualize the , , and fluid pocket while avoiding contact with the or fetal parts. Performed in a sterile environment, it typically begins with cleaning the maternal and administering at the insertion site. A 20- to 22-gauge spinal needle, selected based on the depth to the amniotic cavity (often 12-20 cm in length), is advanced perpendicularly through the abdominal and uterine walls into a clear pocket of fluid. Fluid is then aspirated using a , with 20-30 mL typically extracted for diagnostic purposes, after which the needle is withdrawn and the site monitored for bleeding. Timing for is generally between 15 and 20 weeks of in the second for prenatal , such as detecting chromosomal abnormalities or defects, though it can be performed earlier in select cases or later in the third to assess fetal maturity. Indications include , abnormal screening results, or family history of genetic disorders, with confirming and prior to the . Potential risks of amniocentesis include , with procedure-related rates estimated at 0.1% to 0.5% when performed by experienced providers using , though some studies report up to 0.9%. Other complications, occurring in less than 1% of cases, encompass maternal or fetal , amniotic fluid leakage leading to preterm labor, and rare instances of fetal from needle contact. Post-procedure monitoring involves rest and observation for signs of or contractions, with the overall risk profile improved by real-time guidance. For therapeutic purposes, amnioreduction involves a similar ultrasound-guided needle insertion to larger volumes of excess amniotic fluid in cases of symptomatic , often 1-2 liters per session, to alleviate maternal discomfort and reduce preterm delivery risks. This variant uses sterile technique and may require multiple procedures, with complication rates comparable to diagnostic . As an alternative when amniotic fluid analysis is insufficient, cordocentesis ( umbilical blood sampling) collects fetal blood directly from the vessels under , typically after 18 weeks, for rapid karyotyping or hematologic assessment in urgent scenarios.

Diagnostic Analysis

Diagnostic analysis of amniotic fluid involves a range of laboratory tests to evaluate fetal health, maturity, and potential genetic or developmental abnormalities. These tests are typically performed on samples obtained via amniocentesis and provide critical insights into conditions such as chromosomal disorders, lung maturity, infections, neural tube defects, and hemolytic disease. Genetic testing of amniotic fluid is essential for detecting chromosomal abnormalities. Karyotyping, which examines the complete chromosome set from cultured amniocytes, identifies aneuploidies like trisomy 21 (Down syndrome) with detection rates exceeding 99%. Fluorescence in situ hybridization (FISH) offers rapid results by targeting specific chromosomes (e.g., 13, 18, 21, X, Y) for aneuploidy detection, with high sensitivity for common trisomies. Chromosomal microarray analysis (CMA) enhances detection by identifying copy number variations and small deletions/duplications missed by karyotyping, with the cited study reporting additional clinically relevant findings in approximately 6% of cases with normal karyotypes and structural anomalies. Further, whole exome sequencing (WES) of amniotic fluid, often performed as trio analysis (fetus and parents), is gaining clinical utility for detecting monogenic causes in cases with normal CMA results and structural anomalies, with diagnostic yields reported around 20-30% in recent studies as of 2025. Biochemical assays assess fetal lung maturity, a key factor in preterm delivery decisions. The lecithin-sphingomyelin (L/S) ratio measures surfactant phospholipids; a ratio greater than 2:1 indicates mature lungs and low risk of respiratory distress syndrome (RDS). The presence of phosphatidylglycerol (PG), another surfactant component, further confirms maturity when detected alongside a mature L/S ratio, improving predictive accuracy over L/S alone in complicated pregnancies. Infection markers in amniotic fluid help diagnose intra-amniotic infections like chorioamnionitis. Low glucose levels, typically below 15 mg/dL, suggest bacterial and are a specific indicator of , though sensitivity varies (41-55%). Elevated white blood cell counts (>30 cells/mm³) indicate , while identifies bacteria with 80% sensitivity and 91% specificity when positive for organisms or leukocytes. Screening for defects relies on protein markers in amniotic fluid. Elevated levels greater than 2.5 multiples of the median (MoM) signal potential open defects, as AFP leaks from exposed fetal tissues. assay confirms this; its presence in amniotic fluid is highly specific for open defects, as it leaks directly from fetal . Bilirubin levels are assessed to evaluate hemolytic of the and newborn, often due to Rh incompatibility. Spectrophotometric analysis measures the delta optical density at 450 nm (ΔOD450); values above 0.15 indicate severe requiring intervention. Modern advancements include (cffDNA) analysis from amniotic fluid, which enables rapid detection of certain fetal genetic conditions as an alternative to cell culturing (though the fluid collection remains invasive), and is more commonly sourced from maternal blood for non-invasive . For infections, (PCR) on amniotic fluid provides rapid, sensitive detection of microbial DNA, outperforming traditional cultures in identifying subclinical intra-amniotic infections.

Disorders and Complications

Abnormal Volume Conditions

Abnormal amniotic fluid volume, either deficient or excessive, disrupts fetal and maternal-fetal , occurring in approximately 4% (range 0.5-8%) of pregnancies for and 1-2% for . These conditions arise from an imbalance in amniotic fluid and , primarily involving fetal output, , and transmembranous . In cases, fetal urinary tract anomalies contribute to about 50% of second-trimester diagnoses, leading to reduced fluid . Oligohydramnios refers to insufficient amniotic fluid, diagnosed when the (AFI) is less than 5 cm or the single deepest vertical pocket measures under 2 cm on , deviating from normal ranges of 5-25 cm. Common causes include fetal , bladder outlet obstruction, (), and such as in cases of fetal growth restriction or maternal hypertension. This condition restricts fetal movement and lung expansion, resulting in and the , characterized by facial dysmorphism, limb contractures, and skeletal abnormalities. Short-term outcomes often involve intrauterine growth restriction, increased risk of , and higher rates of cesarean delivery due to fetal distress. Polyhydramnios involves excess fluid accumulation, identified by an of 24 cm or greater or a single deepest vertical pocket greater than 8 cm. Etiologies encompass fetal aneuploidies like trisomies 21, 18, or 13; maternal diabetes mellitus; and twin-twin transfusion in . The excess stems from increased fetal production or impaired swallowing, overwhelming reabsorption mechanisms. Risks include preterm labor, , , and postpartum hemorrhage for the mother, alongside for the fetus. Short-term fetal outcomes may feature macrosomia, particularly in diabetic pregnancies, and respiratory distress due to delayed maturation. Management of both conditions emphasizes close monitoring through serial ultrasounds, non-stress tests, and biophysical profiles to assess fetal well-being, without specific volume-altering interventions detailed here. Early detection allows for timely obstetric planning to mitigate immediate impacts. Chorioamnionitis represents a significant infection of the amniotic fluid and fetal membranes, primarily resulting from ascending bacterial pathogens such as Group B Streptococcus and Escherichia coli that traverse the cervix and gain access to the intrauterine environment. This condition is characterized by acute inflammation of the chorion and amnion, often occurring during labor but potentially earlier in pregnancy. Common clinical symptoms include maternal fever exceeding 38°C, uterine tenderness, maternal tachycardia greater than 100 beats per minute, and fetal tachycardia above 160 beats per minute, which signal the inflammatory response and potential fetal distress. The incidence of clinical chorioamnionitis varies, affecting approximately 1-4% of all births in the United States, with rates rising to 10-15% among preterm deliveries due to prolonged membrane exposure and immature cervical barriers. In global analyses, the pooled incidence stands at about 4.1%, though it ranges widely from 0.6% to 19.7% depending on diagnostic criteria and population factors. Preterm premature rupture of membranes (PPROM), defined as spontaneous rupture before 37 weeks of without the onset of labor, compromises and heightens the risk of ascending infections by allowing bacterial entry into the amniotic . This defect leads to amniotic fluid leakage, which not only predisposes to but also facilitates intra-amniotic infection, with chorioamnionitis developing in 13-60% of affected cases, particularly as latency periods extend. PPROM accounts for about one-third of preterm births and is associated with maternal risk factors such as prior cervical procedures or infections, exacerbating the pathway to chorioamnionitis through disrupted barrier function. Amniotic fluid embolism, a rarer but life-threatening complication linked to membrane disruption during labor or delivery, occurs when amniotic fluid components enter the maternal bloodstream, triggering an anaphylactoid reaction and systemic inflammation. Its pathophysiology involves fetal squamous cells, mucin, and other debris obstructing pulmonary vessels, leading to acute , right ventricular failure, and subsequent left ventricular dysfunction. Symptoms manifest abruptly as cardiovascular collapse with profound , , resembling , and often seizures or altered mental status. The incidence is estimated at 1 in 15,200 to 1 in 53,800 deliveries worldwide, underscoring its rarity yet high maternal mortality rate of up to 60%. Diagnosis of amniotic fluid infections relies on a combination of clinical signs and laboratory markers, including elevated levels of interleukin-6 (IL-6) in amniotic fluid, which serves as a sensitive indicator of intra-amniotic with concentrations often exceeding 2.6 ng/mL in affected cases. Maternal serum (CRP) levels above 8 mg/L also correlate with infection, though amniotic fluid IL-6 demonstrates superior predictive value over CRP for confirming microbial invasion. Amniotic fluid cultures remain the gold standard for identifying specific pathogens like Group B , while and white blood cell counts provide rapid but less specific insights into the inflammatory milieu. Intra-amniotic infections carry substantial long-term risks for the neonate, including an elevated incidence of due to injury from inflammatory cytokines crossing the immature blood-brain barrier. Preterm infants exposed to chorioamnionitis face a 2- to 4-fold increased risk of , particularly when combined with histologic confirmation of placental . Additionally, these infections heighten the likelihood of , with early-onset cases linked to maternal-fetal transmission and associated neurodevelopmental impairments such as speech delays persisting to 18 months corrected age. Preventive strategies for infection in PPROM emphasize prophylaxis to mitigate ascending pathogens and prolong latency. The recommended regimen, per guidelines, involves intravenous and erythromycin for 48 hours, followed by oral amoxicillin and erythromycin for five days, reducing chorioamnionitis risk by up to 30% and delaying delivery by about seven days. This approach targets common urogenital without promoting resistance when limited to short courses, thereby improving neonatal outcomes in high-resource settings.

Therapeutic and Research Applications

Medical Interventions

Medical interventions involving amniotic fluid primarily aim to address imbalances in fluid volume or associated complications during pregnancy, enhancing maternal and fetal outcomes through targeted procedures. Amnioinfusion, the intrauterine infusion of sterile saline solution, is employed to treat or repetitive variable fetal decelerations caused by umbilical cord compression. This procedure increases amniotic fluid volume, thereby diluting if present and improving fetal oxygenation by cushioning the cord. Studies indicate that amnioinfusion effectively relieves variable decelerations in approximately 70-80% of cases during labor, reducing the need for cesarean deliveries and improving neonatal acid-base status. Amnioreduction involves the therapeutic aspiration of excess amniotic fluid in cases of severe , typically guided by to remove 1-2 liters per session and alleviate maternal symptoms such as dyspnea, , and gastroesophageal reflux. This intervention mitigates risks of preterm labor and premature by reducing intrauterine pressure, with median prolongation of pregnancy by 3-4 weeks following the procedure. Complications are infrequent, occurring in 1-4% of cases, including chorioamnionitis or , and the procedure is recommended when maternal respiratory compromise or severe discomfort arises, per Society for Maternal-Fetal Medicine guidelines endorsed by ACOG. In monochorionic twin pregnancies complicated by , serial amnioreduction has demonstrated reduced , with survival of at least one twin in 56% of cases compared to 90% mortality in untreated scenarios, though fetoscopic often yields superior long-term outcomes. For preterm premature rupture of membranes (PPROM), therapeutic strategies include amnioinfusion to restore fluid volume and prolong , alongside systemic administration of antibiotics and corticosteroids to prevent and promote fetal maturity. ACOG recommends a 48-hour course of betamethasone for gestations between 23 0/7 and 34 0/7 weeks to enhance neonatal respiratory outcomes, while broad-spectrum intravenous antibiotics (e.g., and erythromycin or ) are initiated to extend pregnancy by 7 days on average in PPROM cases before 34 weeks. Intra-amniotic instillation of indomethacin has been explored in select PPROM scenarios to suppress and extend , though evidence remains limited to small series showing potential prolongation by 1-2 weeks without increased adverse events. A 2025 ACOG practice advisory highlights increased maternal morbidity risks associated with expectant management in previable and periviable PPROM, recommending patient counseling on these risks and offering abortion care as a management option. Current guidelines emphasize individualized expectant management tailored to , with delivery considered at 34 weeks for PPROM to balance risks and fetal maturity. Historically, amniotic fluid played a pivotal role in the management of Rh isoimmunization, where spectrophotometric analysis of fluid bilirubin levels enabled early detection of fetal hemolysis, guiding intrauterine transfusions and reducing from over 50% to under 20% in affected pregnancies. This era's advancements, including the introduction of for monitoring, laid the groundwork for modern fluid-based interventions, culminating in the widespread of immune globulin prophylaxis by the late to prevent .

Stem Cell and Regenerative Potential

Amniotic fluid stem cells (AFSCs) are multipotent cells primarily isolated from second-trimester amniotic fluid, with the c-kit+ (CD117+) population representing a key subset capable of self-renewal and into lineages from all three germ layers, including neural, hepatic, and osteogenic cells. These cells express markers such as Oct4, Nanog, and SSEA-4, indicating broad stemness without the need for layers or genetic for expansion. Unlike fully pluripotent cells, AFSCs demonstrate restricted potency but high plasticity, enabling their use in modeling human development and disease. AFSCs offer several advantages over embryonic stem cells, including ethical sourcing from routine procedures, lack of tumorigenicity (no formation observed in preclinical models), and rapid proliferation rates—doubling every 36 hours in culture without up to 250 population doublings. These properties make AFSCs a promising autologous or allogeneic resource for regenerative therapies, avoiding ethical concerns associated with destruction and reducing risks of immune rejection or oncogenesis. Key research milestones include the 2007 identification of human AFSCs by De Coppi et al., who demonstrated their isolation via c-kit selection and multilineage potential in animal models. Subsequent preclinical studies have advanced toward clinical translation, such as injection of AFSCs during for repair in sheep models, where cells promoted neural tissue coverage and functional recovery without adverse effects. As of 2025, early-phase clinical trials exploring AFSC-based therapies remain limited, though emerging research on amniotic fluid stem cell-derived extracellular vesicles (AFSC-EVs) shows promise for fetal therapies, including treatment of in preclinical models (as of 2024), and advancements in clinical-grade allogeneic AFSC banking support future applications. In regenerative applications, AFSCs have shown promise in , such as seeding them onto scaffolds for reconstruction in models, where they differentiated into urothelial and cells to restore function post-injury. For , topical or injected AFSCs accelerate closure of full-thickness skin defects in mice by secreting growth factors like VEGF and modulating inflammation. Additionally, their immunomodulatory effects—suppressing T-cell proliferation and promoting regulatory T cells—hold potential for treating autoimmune diseases, as evidenced by AFSC-derived extracellular vesicles alleviating symptoms in mouse models. Collection of AFSCs occurs via standard , yielding 10-20 mL of fluid from which cells are isolated and expanded; banking involves in DMSO-based media, achieving post-thaw viability exceeding 90% while maintaining potential and genetic stability. Public and private biobanks now store clinical-grade AFSC lines, enabling off-the-shelf use. Despite these advances, challenges persist, including scalability for large-volume production to meet therapeutic demands, regulatory hurdles such as FDA requirements for Phase I/II trials demonstrating long-term , and risks of microbial during from amniotic samples. Ongoing addresses these through optimized protocols and GMP-compliant .

References

  1. [1]
    Amniotic fluid: MedlinePlus Medical Encyclopedia
    Oct 15, 2024 · Amniotic fluid is a clear, slightly yellowish liquid that surrounds the unborn baby (fetus) during pregnancy. It is contained in the amniotic sac.Missing: function composition
  2. [2]
    Embryology, Amniotic Fluid - StatPearls - NCBI Bookshelf
    Amniotic fluid surrounds the embryo and fetus during development and has a myriad of functions. Physically, it protects the fetus in the event the maternal ...
  3. [3]
    Sonography Evaluation of Amniotic Fluid - StatPearls - NCBI Bookshelf
    Jan 22, 2025 · Amniotic fluid provides a protective environment, facilitates movement, supports temperature regulation, and contributes to the development of ...
  4. [4]
    Amniotic Fluid Problems/Hydramnios/Oligohydramnios
    Amniotic fluid helps protect and cushion the fetus and plays an important role in the development of many of the fetal organs including the lungs, kidneys, and ...Missing: composition | Show results with:composition
  5. [5]
    Amniotic Fluid: Physiology and Assessment | GLOWM
    In the first half of pregnancy, amniotic fluid is derived from fetal and possibly maternal compartments. Water and solutes freely traverse fetal skin and may ...
  6. [6]
    Catalytic ferrous iron in amniotic fluid as a predictive marker of ... - NIH
    By the 3rd trimester, approximately 80% of amniotic fluid consists of fetal urine, and the other 20% of amniotic fluid is derived from oral, nasal, tracheal ...
  7. [7]
    Fetal Development and Physiology | Obgyn Key
    Mar 31, 2019 · Fetal urine is the primary source of amniotic fluid, and outputs at term vary from 400 to 1200 mL/day. Between 20 and 40 weeks' gestation, fetal ...Amniotic Fluid Volume · Hormones · Development<|control11|><|separator|>
  8. [8]
    Maternal-fetal fluid balance and aquaporins - PubMed Central - NIH
    Aquaporins (AQPs) form specific water channels that allow the rapid transcellular movement of water in response to osmotic/hydrostatic pressure gradients.
  9. [9]
    Cell-Free Amniotic Fluid and Regenerative Medicine - NIH
    Nov 17, 2022 · The soluble fraction consists of water, electrolytes/small molecules, proteins/peptides, carbohydrates, lipids, nucleic acids, hormones and ...
  10. [10]
    Human and ovine amniotic fluid composition differences - PubMed
    Results: Mean (+/-SEM) amniotic fluid sodium concentration (134.6+/-1.9 vs. 127.1+/-2.0 mEq/1) was greater and potassium (4.6+/-0.1 vs. 6.1+/-0.6 mEq/l) and ...Missing: levels | Show results with:levels
  11. [11]
    Biochemical composition of amniotic fluid in pregnancies ... - PubMed
    The concentrations of sodium, potassium, chloride, bicarbonate, calcium, glucose, osmolality, pH, total protein content and albumin were determined in each ...<|control11|><|separator|>
  12. [12]
    Amniotic fluid characteristics and its application in stem cell therapy
    Amniotic fluid (AF) is a clear yellow fluid that surrounds the fetus during pregnancy. The amniotic sac consists of 2 layers: the amnion and the chorion.
  13. [13]
    Vernix Caseosa - StatPearls - NCBI Bookshelf
    Vernix caseosa is a physiological, viscous biofilm that is produced by desquamated fetal skin and sebaceous glands covering the fetus at the third trimester ...Vernix Caseosa · Cellular Level · FunctionMissing: meconium | Show results with:meconium<|control11|><|separator|>
  14. [14]
    UNRAVELING THE MYSTERY OF VERNIX CASEOSA - PMC - NIH
    Vernix performs an epidermal barrier function in utero to facilitate epidermal growth underneath it and acts as a hydrophobic barrier against amniotic fluid ...
  15. [15]
    Impact of maternal posture on fetal physiology in human pregnancy
    The buoyant forces of the amniotic fluid being displaced by the floating fetal volume interact with gravitational forces acting on the fetal mass according to ...
  16. [16]
    Antimicrobial Properties of Amniotic and Chorionic Membranes - NIH
    Human beta-defensin is a large group of natural antibacterial proteins produced by a number of epithelial cells including the chorioamniotic membranes (17, 18).
  17. [17]
    Human β-Defensin-2: A natural anti-microbial peptide present ... - NIH
    Human β-Defensin-2: A natural anti-microbial peptide present in amniotic fluid participates in the host response to microbial invasion of the amniotic cavity.
  18. [18]
    Questioning the fetal microbiome illustrates pitfalls of low-biomass ...
    Amniotic fluid has antimicrobial properties, being enriched for example in lysozyme, human β-defensin 2 (ref.) and GP340 (DMBT1), which binds and ...
  19. [19]
    Neonatal thermal response to childbirth: Vaginal delivery vs ...
    Dec 9, 2020 · The foetal temperature is approximately 0.2–0.5°C higher than the maternal temperature in utero and the foetus' peripheral and core temperatures ...Missing: capacity | Show results with:capacity
  20. [20]
    The development of the amnion in mice and other amniotes - PMC
    Oct 17, 2022 · The amnion is an extraembryonic tissue that evolutionarily allowed embryos of all amniotes to develop in a transient and local aquatic environment.
  21. [21]
    Amniotic Fluid and Ocean Water: Evolutionary Echoes, Chemical ...
    Sep 13, 2025 · Interstitial fluid electrolyte concentrations (Na+ ~140 mmol/L; Cl− ~103 mmol/L; K+ ~4 mmol/L; Ca2+ ~1.2 mmol/L; Mg2+ ~0.7 mmol/L) closely ...Missing: osmolarity | Show results with:osmolarity
  22. [22]
    Fetal lung liquid: a major determinant of the growth and ... - PubMed
    Fetal lung liquid plays a crucial role in the growth and development of the lungs by maintaining them in a distended state.
  23. [23]
    Physiological factors in fetal lung growth - PubMed - NIH
    (b) Adequate amount of amniotic fluid: oligohydramnios retards lung growth ... fetal breathing movements or the volume of fluid within the potential ...
  24. [24]
    Embryology, Amniotic Fluid - PubMed
    Jul 17, 2023 · It provides the necessary fluid, space, and growth factors to allow normal development and growth of fetal organs such as the musculoskeletal ...
  25. [25]
    Amniotic Fluid Disorders: From Prenatal Management to Neonatal ...
    Mar 16, 2023 · It allows fetal movements, and thus the development of the musculoskeletal system, and at the same time prevents compression of the ...2. Amniotic Fluid Volume... · 4. Oligohydramnios · 6. Polyhydramnios
  26. [26]
    Trophic effect of amniotic fluid on fetal gastrointestinal development
    We conclude that fetal swallowing of amniotic fluid is essential in fetal gastrointestinal development, possibly via luminal trophic actions of peptides ...
  27. [27]
    Amniotic fluid: Source of trophic factors for the developing intestine
    This renewal of epithelial cells starts in the fetal life under the influence of many GIT peptides by swallowing amniotic fluid (AF). Development and maturation ...
  28. [28]
    Fetal swallowing: relation to amniotic fluid regulation - PubMed - NIH
    In summary, fetal swallowing activity contributes importantly to fetal and amniotic fluid homeostasis, and fetal somatic and gastrointestinal development.
  29. [29]
    Factors controlling nutrient availability to the developing fetus in ...
    Swallowing of amniotic fluid provides a rich source of nutrients for utilization by the fetal intestine and other tissues [67].Fetal Nutrient Restriction · Placental Fluids · Placental Nutrient Transport
  30. [30]
    The role of amniotic fluid in fetal nutrition - PubMed
    We conclude that amniotic fluid provides 10% to 14% of the nutritional requirements of the normal fetus, and that amniotic fluid contains a potent and as yet ...
  31. [31]
    An acoustic gap between the NICU and womb: a potential risk for ...
    As a consequence of the acoustic properties of the womb, the fetus receives, for the most part, a low-pass filtered version of the auditory environment in the ...
  32. [32]
    Evaluation of fetal exposure to external loud noise using a sheep ...
    The sound energy in amniotic fluid stimulates fetal hearing through a bone conduction route rather than through the external and middle ear systems.
  33. [33]
    The Effect of Musical Stimulation and Mother's Voice on the Early ...
    Aug 11, 2021 · The amniotic fluid surrounding the fetus is an effective transmitter of the melodic contour of the maternal voice. When a mother speaks or sings ...
  34. [34]
    Transport, Metabolism, and Function of Thyroid Hormones in the ...
    Apr 3, 2019 · In this review we summarize the current knowledge about TH delivery, conversions, and function in the developing mammalian brain.
  35. [35]
    Steroids, Pregnancy and Fetal Development - PMC - PubMed Central
    Jan 22, 2020 · Maternal glucocorticoids critically rise during pregnancy reaching up to a 20-fold increase of mid-pregnancy concentrations.
  36. [36]
    Study on amniotic fluid metabolism in the second trimester of ... - NIH
    Many significantly changed metabolites were identified between amniotic fluid samples from Trisomy 21 pregnancies and normal euploid pregnancies.Missing: exchange | Show results with:exchange
  37. [37]
    Physiology of amniotic fluid volume regulation - PubMed - NIH
    AFV normally undergoes characteristic changes across gestation in which it increases from 10-20 ml at 10 weeks gestation to average 800 ml at 24 weeks.
  38. [38]
    Amniotic fluid volume | Radiology Reference Article - Radiopaedia.org
    Aug 5, 2024 · Change in volume through gestation · 10 weeks gestation: ~10-20 mL · 16 weeks gestation: ~250 mL · 33 weeks gestation: ~800 mL · 38-39 weeks: ...
  39. [39]
    Amniotic Fluid: Color, Smell, Function & Disorders - Cleveland Clinic
    It depends on how far you are in your pregnancy. Your amniotic fluid levels peak at 34 to 36 weeks and then slowly decrease as you reach your due date (40 weeks) ...
  40. [40]
    Association between amniotic fluid evaluation and fetal biometry
    May 4, 2018 · Other factors such as fetal male gender or maternal BMI (overweight and class I obesity) may also have an impact on the amount of amniotic fluid ...
  41. [41]
    Maternal hydration for increasing amniotic fluid volume in ...
    Simple maternal hydration appears to increase amniotic fluid volume and may be beneficial in the management of oligohydramnios and prevention of oligohydramnios ...
  42. [42]
    Regulation of amniotic fluid volume - PubMed
    Amniotic fluid volume is thus a function both of the amount of water transferred to the gestation across the placental membrane, and the flux of water across ...
  43. [43]
    Amniotic fluid index measurements during pregnancy - PubMed
    The AFI was determined by the summation of the vertical diameter of the largest pocket in each of the four quadrants. All amniotic fluid studies were conducted ...
  44. [44]
    Amniotic fluid index | Radiology Reference Article | Radiopaedia.org
    Aug 5, 2024 · The normal range for amniotic fluid volumes varies with gestation 4. Median AFI level is ~14 cm from week 20 to week 35, after which the ...
  45. [45]
    Single deepest vertical pocket or amniotic fluid index as evaluation ...
    Jun 10, 2015 · Oligohydramnios was defined as AFI ≤ 5 cm or the absence of a pocket measuring at least 2 × 1 cm. The diagnosis of oligohydramnios was followed ...<|control11|><|separator|>
  46. [46]
    Monitoring fetal growth - NCBI Bookshelf - NIH
    It is current practice for women with low risk pregnancies to have symphysis-fundal height (SFH) measurements during the third trimester to monitor growth of ...
  47. [47]
    Amniotic fluid dynamics - PubMed
    Amniotic fluid was once considered to be a stagnant pool, approximately circulating with a turnover time of one day. Adequate amniotic fluid volume is ...Missing: rate | Show results with:rate
  48. [48]
  49. [49]
    Biological Pathways Leading to Preterm Birth - NCBI
    The increased action of estrogen leads to the formation of many estrogen-dependent CAPs, such as CX-43, oxytocin receptors, and prostaglandins, that promote ...
  50. [50]
    Prelabor Rupture of Membranes - ACOG
    Prelabor rupture of membranes (PROM) that occurs preterm complicates approximately 2–3% of all pregnancies in the United States.
  51. [51]
    Preterm and Term Prelabor Rupture of Membranes (PPROM ... - NCBI
    Oct 31, 2024 · Birth within 7 days of membrane rupture occurs in at least 50% of patients with PPROM. Although rare, cessation of fluid leakage with ...
  52. [52]
    The ferning and nitrazine tests of amniotic fluid between 12 and 41 ...
    Reported accuracies are 84 to 100% for the ferning test and 87 to 97% for the nitrazine test. Our study was designed to determine if these tests are applicable ...
  53. [53]
    Premature Rupture of Membranes: First-Level Tests - Healthline
    Jan 8, 2016 · Nitrazine Test​​ The strips will turn blue if the pH is greater than 6.0. A blue strip means it's more likely the membranes have ruptured.Symptoms · Diagnosis · Complications · Treatment
  54. [54]
    Amniocentesis - StatPearls - NCBI Bookshelf - NIH
    Aug 14, 2023 · It is a prenatal invasive procedure and is done under ultrasound guidance. This procedure uses ultrasonography to guide the catheter or needle ...
  55. [55]
    How to perform an amniocentesis - Obstetrics and Gynecology - Wiley
    Dec 1, 2014 · The procedure must be performed from 16 weeks of gestation onwards, as confirmed by ultrasound. A 20–22-G needle must be used under continuous ...Procedure · Ultrasound Evaluation · Needle Insertion
  56. [56]
    Amniocentesis - Mayo Clinic
    During amniocentesis, an ultrasound wand (transducer) is used to show a baby's position in the uterus on a monitor. A sample of amniotic fluid, which contains ...
  57. [57]
    Amniocentesis - ACOG
    Amniocentesis usually is done between 15 and 20 weeks of pregnancy, but it also can be done up until you give birth. It is your choice whether you want to have ...
  58. [58]
    Amniocentesis: Purpose, Procedure, Risks & Recovery
    The test usually happens between 15 and 20 weeks of pregnancy (during the second trimester). In some cases, it happens in the third trimester. Your healthcare ...
  59. [59]
    Diagnostic amniocentesis - UpToDate
    Oct 7, 2025 · Amniocentesis is also performed as a therapeutic procedure to remove excess amniotic fluid, such as in symptomatic polyhydramnios or twin-twin ...
  60. [60]
    Risk of miscarriage following amniocentesis or chorionic villus ...
    A total of 580 miscarriages occurred following 63 723 amniocentesis procedures, resulting in a weighted risk of pregnancy loss of 0.91% (95% CI, 0.73-1.09%).
  61. [61]
    Amniocentesis | Johns Hopkins Medicine
    The risk of miscarriage is considered less than 1% after an amniocentesis in the second trimester of pregnancy. This is only slightly higher than the normal ...
  62. [62]
    Amnioreduction for Polyhydramnios in a Consecutive Series at ... - NIH
    Apr 22, 2024 · Our study confirms the finding that amnioreduction for polyhydramnios in singleton and twin pregnancies is a safe procedure. The ...
  63. [63]
    Cordocentesis: Purpose, Procedure, Risks & Results
    Oct 31, 2022 · Cordocentesis is a prenatal test that takes a sample of blood from a fetus's umbilical cord to detect abnormalities. It can diagnose certain ...
  64. [64]
    Fetal blood sampling in mid‐pregnancy: does it still have a role in ...
    Nov 2, 2020 · For most of these indications, cordocentesis has been replaced by amniocentesis owing to the advancement of laboratory technologies that ...
  65. [65]
    Lecithin Sphingomyelin Ratio - StatPearls - NCBI Bookshelf
    Mar 27, 2025 · The lecithin-to-sphingomyelin ratio (L/S ratio) is one of several methods used to assess fetal lung maturity (FLM).
  66. [66]
    Prenatal Testing for Down Syndrome - UCSF Health
    It takes about two weeks to receive the results. Amniocentesis detects most chromosomal disorders with a high degree of accuracy. There is a low risk of ...
  67. [67]
    Chromosome FISH, Amniotic Fluid with Reflex to ... - ARUP Lab
    For rapid detection of aneuploidy involving chromosomes 13, 18, 21, X, and Y. If the FISH results are abnormal, the specimen will reflex to chromosome analysis.
  68. [68]
    Chromosomal Microarray versus Karyotyping for Prenatal Diagnosis
    Dec 6, 2012 · Chromosomal microarray analysis identifies a genetic cause in an additional 12 to 15% of affected children, as compared with the current ...
  69. [69]
    Lecithin-Sphingomyelin Ratio (Amniotic Fluid)
    A ratio of more than 2:1. This means that your baby has mature lungs and is ready for life outside the uterus. In some cases, your doctor may want to see ...
  70. [70]
    Phosphatidylglycerol determination on amniotic fluid 10,000 × g ...
    Phosphatidylglycerol determination is an accurate predictor of fetal lung maturity, and predicts lung immaturity more correctly than do the L/S ratio and shake ...
  71. [71]
    Low amniotic fluid glucose levels are a specific but not a ... - PubMed
    The sensitivity of a low amniotic fluid glucose level to detect both types of intrauterine infection ranged from 41% to 55%, depending on the threshold used.
  72. [72]
    Evaluating rapid diagnostic tests of intra-amniotic infection: Gram ...
    RESULTS: The Gram stain is 80% sensitive and 91% specific when a positive is considered the presence of white blood cells or bacteria. Amniotic fluid glucose ...
  73. [73]
    Volume 3, Chapter 116. Alpha-Fetoprotein and Neural Tube Defects
    AFP concentration in amniotic fluid is approximately 150 times less than in fetal serum. In the maternal circulation, AFP levels rise until the 30th gestational ...ALPHA-FETOPROTEIN · NEURAL TUBE DEFECTS · MANAGEMENT<|control11|><|separator|>
  74. [74]
    Acetylcholinesterase, Amniotic Fluid - Mayo Clinic Laboratories
    The presence of acetylcholinesterase in amniotic fluid is consistent with open neural tube defects and, to a lesser degree, ventral wall defects.
  75. [75]
    Does midtrimester ΔOD450 of amniotic fluid reflect severity of Rh ...
    Serial amniotic fluid values of delta optical density at 450 nm were studied to predict the severity of Rh disease. A value >0.15 indicated severe Rh ...
  76. [76]
    Polymerase chain reaction in the detection of microbes in amniotic ...
    This review concentrates on broad-spectrum or universal bacterial PCR for detection of bacterial DNA in amniotic fluid and on PCR assays for certain clinically ...Missing: modern advancements
  77. [77]
    Oligohydramnios - StatPearls - NCBI Bookshelf
    May 4, 2025 · The incidence of oligohydramnios is <1% in preterm pregnancies.[23][24] However, rates appear slightly higher in patients with preterm labor and ...
  78. [78]
    Polyhydramnios - StatPearls - NCBI Bookshelf - NIH
    Nov 9, 2024 · Polyhydramnios is a pathological condition characterized by an excess of amniotic fluid associated with increased rates of maternal and neonatal morbidity and ...
  79. [79]
    Polyhydramnios: Causes, Diagnosis and Therapy - PMC - NIH
    The risk of fetal malformation in cases with severe polyhydramnios has been reported to increase to 11 %, but this figure is still discussed controversially.
  80. [80]
    Chorioamnionitis - StatPearls - NCBI Bookshelf - NIH
    Chorioamnionitis is an infection that can occur before labor, during labor, or after delivery. It can be acute, subacute, or chronic.Continuing Education Activity · Introduction · Etiology · Epidemiology
  81. [81]
    Diagnosis and Management of Clinical Chorioamnionitis - PMC - NIH
    Epidemiology (incidence and risk factors)​​ Overall, 1–4% of all births in the US are complicated by chorioamnionitis [2]; however, the frequency of ...
  82. [82]
    The Consequences of Chorioamnionitis: Preterm Birth and Effects ...
    Chorioamnionitis is a common cause of preterm birth. Clinical chorioamnionitis, characterised by maternal fever, leukocytosis, tachycardia, uterine tenderness, ...
  83. [83]
    Chorioamnionitis: An Update on Diagnostic Evaluation - PMC - NIH
    A recent meta-analysis of global incidence of clinical chorioamnionitis reported a pooled incidence of 4.1%; however, rates ranged from 0.6% to 19.7% and ...
  84. [84]
    Contemporary Diagnosis and Management of Preterm Premature ...
    Maternal complications include clinically evident intra-amniotic infection, which occurs in 13% to 60% of women with preterm PROM as compared with 1% at term, ...
  85. [85]
    Risk Factors and Outcomes of Preterm Premature Rupture of ... - NIH
    The outcomes associated with PPROM include prematurity, oligohydramnios, abruption placentae, intrauterine infection, and chorioamnionitis [2,14,15]. Most ...
  86. [86]
    Amniotic Fluid Embolism - StatPearls - NCBI Bookshelf
    Jan 10, 2024 · Amniotic fluid embolism (AFE) is a critical obstetric emergency marked by sudden cardiorespiratory collapse and disseminated intravascular ...Continuing Education Activity · Introduction · Pathophysiology · Evaluation
  87. [87]
    Amniotic fluid embolism - PMC - PubMed Central
    Clinical signs and symptoms are acute dyspnea, cough, hypotension, cyanosis, fetal bradycardia, encephalopathy, acute pulmonary hypertension, coagulopathy etc.
  88. [88]
    AMNIOTIC FLUID EMBOLISM: AN EVIDENCE-BASED REVIEW - PMC
    The classic presentation of AFE is characterized by sudden cardiovascular collapse, with profound systemic hypotension, cardiac dysrhythmia, cyanosis, dyspnea ...
  89. [89]
    Amniotic fluid embolism syndrome: analysis of the United States ...
    Oct 8, 2021 · The reported incidence of AFE ranges from 1 in 15,200 to 1 in 53,800 deliveries worldwide. Recognition of the true incidence and mortality rates ...
  90. [90]
    A rapid interleukin-6 bedside test for the identification of intra ... - NIH
    Multiple studies have shown that amniotic fluid (AF) IL-6 concentrations are superior to AF white blood cell (WBC) counts, glucose, Gram stain or equivalent to ...
  91. [91]
    Predictive value of intra-amniotic and serum markers for ... - PubMed
    The AF MMP-9 has a better overall diagnostic performance than the AF IL-6 and maternal serum CRP in predicting intra-amniotic infection.
  92. [92]
    Maternal serum C-reactive protein concentration and intra-amniotic ...
    Aug 16, 2017 · Amniotic fluid IL-6 and matrix metalloproteinase 8 have been traditionally considered as the markers for the identification of IAI [7, 33–35].
  93. [93]
    Chorioamnionitis in the Development of Cerebral Palsy - NIH
    Preterm HCA may be a risk factor for CP, whereas CCA is not. An association with term and preterm CP was found for CCA, but only with term CP for HCA. Cerebral ...Cp In Cca Patients · Cp In Hca Patients · Cca In Cp Patients
  94. [94]
    Current management and long-term outcomes following ... - NIH
    Multiple signs and symptoms are consistent with chorioamnionitis, diagnosed prior to delivery, and as a result, diagnostic criteria may vary by provider and ...Gbs · Clinical Outcomes · Neonatal Management<|separator|>
  95. [95]
    Chorioamnionitis and Neonatal Outcomes - PMC - NIH
    Chorioamnionitis is associated with an increased incidence of speech delay and hearing loss at 18 months of corrected age in infants born very preterm.
  96. [96]
    The Management of Pregnancy Complicated with the Previable ...
    Aug 22, 2022 · ACOG recommends antibiotic prophylaxis as a two-day therapy with ampicillin i.v. and erythromycin followed by five-day oral prophylaxis with ...
  97. [97]
    A New Antimicrobial Combination Prolongs the Latency Period ... - NIH
    While several antibiotic regimens have been proposed for preterm PROM, the combination of ampicillin/amoxicillin with erythromycin is among the most widely-used ...<|control11|><|separator|>
  98. [98]
    Transcervical Amnioinfusion - AAFP
    Feb 1, 1998 · Intrapartum amnioinfusion appears to improve outcomes in gravidas with variable decelerations or thick meconium during labor. The procedure ...Abstract · Indications · Risks · Transcervical Amnioinfusion...
  99. [99]
    Amnioinfusion compared with expectant management in ... - NIH
    Amnioinfusion may significantly improve the latency period, the rate of cesarean delivery, and neonatal outcomes of oligohydramnios.Missing: efficacy | Show results with:efficacy
  100. [100]
  101. [101]
    [PDF] Isolated Amniotic Fluid Disorders - College of Medicine
    Jan 23, 2019 · Consider amnioreduction when severe polyhydramnios leads to maternal respiratory compromise, severe discomfort or both as per SMFM Consult ...
  102. [102]
    Endoscopic Laser Surgery versus Serial Amnioreduction for Severe ...
    Survival rates of 18 to 83 percent have been reported, with rates of neurologic complications ranging from 5 to 58 percent. Fetoscopic laser coagulation of ...<|separator|>
  103. [103]
    Preterm Labor: Prevention and Management | AAFP
    Mar 15, 2017 · A course of corticosteroids is the only antenatal intervention that has been shown to improve postdelivery neonatal outcomes.
  104. [104]
    Rho(D) immunoglobulin (RhoGAM): how it came into being - PubMed
    The story of Rho(D) immunoglobulin (RhoGAM) begins in 1909 with Theobald Smith, Fabyan Professor of Comparative Pathology at Harvard, and ends in the 1960s.
  105. [105]
    Winnipeg Rh Laboratory - Medical Heritage Manitoba
    The Rh Lab was one of the first units in North America to add amniotic fluid spectrophotometry (1961) and intrauterine fluid intraperitoneal transfusions (1964) ...
  106. [106]
    Concise Review: Amniotic Fluid Stem Cells: The Known, the ...
    Dec 23, 2016 · De Coppi et al. demonstrated engraftment, neuronal differentiation and prolonged survival (up to 2 months) of human AFSC transplanted directly ...
  107. [107]
    In Utero Amniotic Fluid Stem Cell Therapy Protects Against ... - NIH
    This study demonstrated that in utero amniotic fluid stem cell therapy for fetal myelomeningocele (MMC) could induce direct coverage of the spinal cord and ...
  108. [108]
    Bladder Transplantation of Amniotic Fluid Stem Cell may Ameliorate ...
    Jan 3, 2017 · The objective is to investigate whether human amniotic fluid stem cells (hAFSCs) grafting into the bladder may influence bladder functional ...Missing: reconstruction | Show results with:reconstruction
  109. [109]
    Amniotic fluid stem cells provide considerable advantages ... - Nature
    Jun 23, 2015 · In this study, we examined the advantages of using human amniotic fluid stem (hAFS) cells in skin wound healing.
  110. [110]
    Amniotic fluid stem cell-derived extracellular vesicles educate type 2 ...
    Amniotic fluid stem cell-derived extracellular vesicles educate type 2 conventional dendritic cells to rescue autoimmune disorders in a multiple sclerosis mouse ...
  111. [111]
    Clinical-grade allogeneic amniotic fluid stem cell banking - NIH
    Sep 26, 2025 · This study offers a comprehensive technical and translational overview of establishing an allogeneic amniotic fluid mesenchymal stem cell bank, ...